Oregon's Death with Dignity law replicated in other states
NASHVILLE, Tenn. (WKRN) — An estimated 66% of Americans said assisted suicide should be legal. Today, it's legal in ten states and Washington D.C.
News 2 's Mark Kelly spoke with the law's original champion.
'For me, it's about honoring how that person wants to live their final days,' said Geoff Sugerman, national legislative director at Death with Dignity, a group that advocates for aid in dying legislation in the U.S.
Sugerman was one of the first in the country to bring to life what is sometimes called Death with Dignity legislation.
'They are at the point in their illness where there is no treatment options left for them.'
The work to pass the new legislation started in Oregon in 1994. By 1997, the Death with Dignity legislation became law. And according to a state report from Oregon, the following year, 16 people chose to use the law and take a prescription to end their life. In 2023, that number rose to 367 people. Sugerman said Oregon's law has become a model for other states.
'There's a really solid and strong process in place that really protects patients and yet still allows this choice for those people who are really at the end of life.'
Sugerman said Oregon's law has four key guardrails to prevent abuse:
The patient must be diagnosed with a terminal illness and two doctors agree that the patient has six months to live.
The patient must be mentally competent to make their own decisions.
The patient must make their decision voluntarily.
And the patient must self-administer the medicine.
Supporters believe these guardrails are critical because they differentiate Death with Dignity from suicide and euthanasia, which is when a doctor deliberately kills a patient. Euthanasia is illegal in the U.S.
'A person with a disability just doesn't qualify to use the law, unless they also have an underlying terminal illness; a person with a mental health issue does not qualify to use the law; a person with Alzheimer's or dementia is not allowed to use the law because they're not deemed capable of making their own healthcare decisions,' said Sugerman.
⏩
Interestingly, a new Gallup poll found 66% percent of Americans not only support assisted suicide, a great many also support euthanasia – and that spans political parties: 79% of Democrats; 72% of Independents; and 61% of Republicans say they support legalizing euthanasia.
'The general public, as it is on most issues, is far ahead of most legislatures in support for this,' said Sugerman.
Ten states and Washington D.C. have legalized physician-assisted suicide. New York and Massachusetts may very well be next. But Sugerman says that here in Tennessee a Death with Dignity law doesn't seem to be on the horizon in the near future.
'We look at states that have strong organizations and strong legislative champions. And those tend to be the states where we focus more of our efforts legislatively,' said Sugerman.
A recent change in Oregon law allows people from other states to travel there for physician-assisted suicide, opening up the procedure to more Americans.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
39 minutes ago
- USA Today
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population. Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 (rVE=29.6%), A/H3N2 (rVE=22.2%), and the B/Victoria lineages (rVE=29.1%). Subgroup analyses confirmed a consistently strong rVE point estimate across age groups, risk factors and previous influenza vaccination status. In participants aged 65 years and older, mRNA-1010 demonstrated an rVE of 27.4%. 'Today's strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults. The severity of this past flu season underscores the need for more effective vaccines,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines.' In a previous Phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine. [1] According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season. [2] More than 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs, as well as widespread disruption to daily life and work. [3] P304 ( NCT06602024 ) is a Phase 3, randomized, observer-blind, active-controlled, case-driven, pivotal efficacy, immunogenicity and safety study. The trial enrolled 40,805 adults aged 50 years and older across 11 countries. Participants were randomly assigned to receive either a single dose of mRNA-1010 or a standard-dose licensed comparator, with a median follow-up of six months. Safety and tolerability of mRNA-1010 were consistent with reported results from a previous Phase 3 study. [4] The majority of solicited adverse reactions (SARs) were mild. Injection site pain was the most common local SAR, and fatigue, headache and myalgia were the most common systemic SARs reported. There were no significant differences between the groups in the rates of unsolicited adverse events, serious adverse events, or adverse events of special interest. Moderna plans to present these data at an upcoming medical conference and submit for peer-reviewed publication. The Company will engage with regulators on filing submissions for mRNA-1010. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's engagement with regulators on filing submissions for its standalone flu vaccine candidate; and the efficacy, safety and tolerability of mRNA-1010. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at . Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Chris Ridley Head of Global Media Relations +1 617-800-3651 Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
CNBC
an hour ago
- CNBC
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and the company's separate combination flu and Covid jab. Moderna in May voluntarily withdrew an application seeking approval of its combination shot targeting Covid-19 and influenza, saying it had plans to resubmit it with efficacy data from the phase three trial on its standalone flu vaccine. That decision came after discussions with the Food and Drug Administration, which is grappling with a massive overhaul under Health and Human Services Secretary Robert F. Kennedy Jr., a prominent vaccine skeptic. With the new data, the company plans to resubmit the application for the combination vaccine and file for approval of its standalone flu shot later this year, Stephen Hoge, the company's head of research and development, said in an interview. If regulators approve the flu vaccine, the company can then advance the combination shot, Hoge said. He added that Moderna expects approvals for both shots next year pending reviews. He said the combination jab simplifies vaccination, which will "help the health-care system" by reducing workloads of doctors and nurses, slashing costs and improving uptake among patients. The company so far appears to be the frontrunner in the race against Pfizer and Novavax to bring a combination shot to the market. While Moderna does not have specific revenue projections for its individual products, Hoge said Covid, flu and respiratory syncytial virus are each multi-billion-dollar markets. "We're obviously hoping that our products allow us to earn our fair share of them," he said. The phase three trial followed more than 40,000 adults ages 50 and above, who were randomly assigned to receive a single dose of Moderna's shot, called mRNA-1010, or a standard competitor vaccine. Moderna's shot was 26.6% more effective than the other vaccine in the overall study population. The mRNA-1010 jab also demonstrated strong efficacy for each of the major influenza strains in the shot, including A/H1N1, A/H3N2 and the B/Victoria lineages. Moderna said the vaccine's benefit was consistent across different age groups, people with various risk factors and previous vaccination status against the flu. In adults ages 65 and older, the shot was 27.4% more effective than the standard flu vaccine. The efficacy results are "a significant milestone in our effort to reduce the burden of influenza in older adults," Moderna CEO Stephane Bancel said in a release. "The severity of this past flu season underscores the need for more effective vaccines." Moderna cited data from the Centers for Disease Control and Prevention showing that seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024 to 2025 season of the virus. More than 600,000 Americans were hospitalized due to flu-related illness last year, according to the CDC. The mRNA-1010 vaccine's safety data was consistent with previous results from another phase three study on the shot. Shares of Moderna are down more than 30% for the year, fueled in large part by a string of moves by the Trump administration to change vaccine policy and undermine immunizations. The administration in May canceled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans. When asked about the uncertain regulatory environment in the U.S., Hoge said Moderna is engaging closely with the FDA to understand what its requirements are and how to satisfy them. "I believe, as relates to flu, I think we've got a pretty clear path," he said.
Yahoo
an hour ago
- Yahoo
Gene discovery may lead to ‘exercise pill' for Alzheimer's patients
Scientists have identified specific brain cells which respond most to exercise, an advance that could lead to a pill to boost the benefits Alzheimer's patients receive from exercise. The study, published in the journal Nature Neuroscience, reveals further insights into the connection between exercise and the brain and can point to future drug targets. 'While we've long known that exercise helps protect the brain, we didn't fully understand which cells were responsible or how it worked at a molecular level,' said study co-author Christiane D. Wrann from Mass General Brigham in the US. 'Now, we have a detailed map of how exercise impacts each major cell type in the memory centre of the brain in Alzheimer's disease,' Dr Wrann said. In the study, scientists focused on the brain's hippocampus – a key region for memory and learning that is damaged early in Alzheimer's disease. Using cutting-edge technology to peer into the molecules inside individual cell nuclei, researchers looked at the gene activity in single cells for an in-depth understanding of diseases like Alzheimer's. They used a common mouse model for Alzheimer's disease, which ran on wheels for the benefit of improved memory compared to the sedentary rodents. Researchers then analysed the individual cells in the brain of these mice. They found that the rodents running on wheels had changed activity in Alzheimer's disease-associated microglia cells, which are located throughout the brain and spinal cord. Scientists also found altered activity linked to exercise in a specific cell type called Oligodendrocyte progenitor cells, which are linked to blood vessels in the brain. They probed even further to find that a gene named Atpif1 was an important regulator in creating new nerve cells in the brain. 'That we were able to modulate newborn neurons using our new target genes set underscores the promise our study,' said study lead author Joana Da Rocha. Researchers then validated their discoveries in a large dataset of human Alzheimer's brain tissue, finding striking similarities. 'This work not only sheds light on how exercise benefits the brain but also uncovers potential cell-specific targets for future Alzheimer's therapies,' said Nathan Tucker, another author of the study. 'Together, these data present a comprehensive resource for understanding the molecular mediators of neuroprotection by exercise in Alzheimer's disease,' scientists wrote.
